Dechra announces agreement to acquire Gallant Pet, Inc.

09 November 2026

Dechra has signed an agreement to acquire Gallant Pet, Inc., a U.S.-based animal health biotechnology company pioneering off-the-shelf mesenchymal stromal cell therapies for pets. This complementary transaction is aligned with Dechra’s long-term strategy to serve unmet needs in specialty care.  

Gallant has become a recognized leader in regenerative medicine with capabilities that will further strengthen Dechra’s ability to advance animal health and welfare while delivering sustainable growth. 

Completion of the transaction remains subject to customary closing conditions. The parties have agreed that the terms of the transaction will remain confidential. 

Media Contact:
Lauren Dorsch, VP, Corporate Affairs and Commercial Communications, Dechra
Email: lauren.dorsch@dechra.com